JV-394 / UT MD Anderson Cancer Center - LARVOL DELTA

The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today announced that the Food and Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for a novel chimeric antigen receptor (CAR) T cell therapy. (Mirage News) - "The cell therapy, developed in the laboratory of Sattva Neelapu, M.D., professor of Lymphoma & Myeloma at UT MD Anderson, will enter a Phase 1 clinical trial for patients with relapsed or refractory CD94+ T/NK cell lymphomas. CTMC will manufacture the therapy for the trial, which Neelapu will lead....Researchers will evaluate three dose levels to help identify the maximum tolerated dose. A novel BCMA safety switch has been incorporated into the therapy, which can help eliminate the CAR T cells in the event of unexpected side effects."

IND • Trial status • Cutaneous T-cell Lymphoma • Extranodal Natural Killer/T-cell Lymphoma • Hepatosplenic T-cell Lymphoma • Natural Killer/T-cell Lymphoma

Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Natural Killer/T-cell Lymphoma • Oncology • CD8 • KLRD1